Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPX159 in Moderate to Severe RLS
NCT01521663Phase 2Completed
- Sponsor
- Impax Laboratories
- Start
- Nov 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IPX159 in restless legs syndrome (RLS), sponsored by Impax Laboratories. Started Nov 2011; status: completed.
02
Drugs
IPX159
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT01521663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01521663.